Clinical Trials Directory

Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma

Mantle Cell Lymphoma is a sub-type of Non-Hodgkin's Lymphoma which is generally considered incurable with current therapy. Our goal is to accrue 59 patients who receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. Our hope is that vaccination will prolong the time which patients will stay in remission from their disease.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : CpG-MCL vaccine, primed T-cells
  • drug : PF-3512676
  • drug : Rituximab
  • procedure : PET-CT scan
  • procedure : Autologous peripheral blood stem cell transplantation
  • procedure : CT scan

Phase: Phase 2


Ages Eligible For Study:

21 Years - 70 Years

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting

Footer Links: